Alpha DNA Investment Management LLC Buys Shares of 10,663 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Alpha DNA Investment Management LLC purchased a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the fourth quarter, Holdings Channel reports. The fund purchased 10,663 shares of the company’s stock, valued at approximately $441,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Summit Investment Advisors Inc. lifted its holdings in Mirum Pharmaceuticals by 8.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company’s stock worth $172,000 after buying an additional 312 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock worth $30,000 after acquiring an additional 357 shares during the period. Legato Capital Management LLC boosted its holdings in Mirum Pharmaceuticals by 7.9% in the fourth quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock valued at $554,000 after acquiring an additional 977 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Mirum Pharmaceuticals by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock valued at $421,000 after purchasing an additional 1,003 shares during the period. Finally, Rhumbline Advisers raised its holdings in Mirum Pharmaceuticals by 2.4% during the 4th quarter. Rhumbline Advisers now owns 53,113 shares of the company’s stock worth $2,196,000 after purchasing an additional 1,236 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on MIRM. HC Wainwright upped their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $58.20.

Mirum Pharmaceuticals Trading Up 0.9 %

NASDAQ:MIRM opened at $39.10 on Friday. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $54.23. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -19.36 and a beta of 1.00. The firm has a fifty day simple moving average of $45.23 and a two-hundred day simple moving average of $43.96.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 2,627 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94. Following the transaction, the chief operating officer now owns 26,961 shares in the company, valued at approximately $1,300,059.42. This represents a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $43,223.84. Following the transaction, the senior vice president now owns 3,524 shares of the company’s stock, valued at $168,870.08. This represents a 20.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 116,473 shares of company stock valued at $5,249,134. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.